David Liu

David Liu

Creator
0 followers

Harvard/Broad Institute professor; pioneer of CRISPR gene editing (base and prime editing) driving biotech innovation.

AI‑Designed PE8 Editors Boost Prime Editing Efficiency
SocialMay 21, 2026

AI‑Designed PE8 Editors Boost Prime Editing Efficiency

Today in @NatureBiotech we report a new suit of PE8 prime editor proteins. PE8 variants were developed from laboratory-evolved PE6 proteins using AI-guided protein redesign. This approach combines recent advances in computational protein design and directed evolution to increase prime...

By David Liu
Adenine Base Editing Reverses Dravet Syndrome in Mice
SocialMay 13, 2026

Adenine Base Editing Reverses Dravet Syndrome in Mice

Today in @ScienceTM, we report the use of in vivo adenine base editing to correct a variant causing Dravet syndrome, a severe childhood epilepsy and neurodevelopmental disorder, substantially ameliorating disease symptoms and extending lifespan in an animal model. 1/13 https://t.co/uQEwWvj94y

By David Liu
Breakthrough Prize Showcases Baby Gene‑Editing Miracle
SocialApr 28, 2026

Breakthrough Prize Showcases Baby Gene‑Editing Miracle

The 2026 Breakthrough Prize ceremony (“the Oscars for science”) celebrated the achievements of many remarkable scientists and their students and collaborators last weekend. Here’s the video of the show: https://t.co/eCHUnDqrYX. And here’s the segment in which Anne Hathaway and Alex...

By David Liu
In‑vivo Base Editing Rescues Zellweger Disorder in Mice
SocialApr 14, 2026

In‑vivo Base Editing Rescues Zellweger Disorder in Mice

Today in @natBME we report an in vivo base editing strategy that corrects a common disease-causing mutation and rescues pathology in a mouse model of Zellweger spectrum disorder (ZSD) and restore peroxisomal function in patient derived cells. This work highlights...

By David Liu
Prime-Edited Therapy Restores Immune Function in Teen
SocialFeb 23, 2026

Prime-Edited Therapy Restores Immune Function in Teen

Below is the story of the first patient treated with a prime-edited therapeutic, developed by @PrimeMedicine in a trial led by Dr. Élie Haddad and his team at CHU Sainte-Justine. This teenager suffered from chronic granulomatous disease (CGD), an immunodeficiency,...

By David Liu